RxDoctor Payments DataLook up a doctor →

Eugenio Angueira-Serrano, MD

Endocrinology, Diabetes & Metabolism · Miami, FLNPI 1578621702

Payments from drug & device makers

$2,234,596in general payments, 2019–2025

Across 3,960 payments — averaging $564.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$996K
  • AbbVie$476K
  • Novo Nordisk$148K
  • Sanofi US Services Inc.$105K
  • Corcept Therapeutics$96K
  • Lilly USA, LLC$65K
  • plus $350K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Regeneron1,481$995,779
AbbVie(2 entities)214$475,503
Novo Nordisk239$147,816
Sanofi US Services Inc.16$104,569
Corcept Therapeutics172$96,096
Lilly USA, LLC243$64,849
Sanofi-aventis U.S. LLC176$60,576
Amgen(2 entities)174$54,898
AstraZeneca(2 entities)64$35,862
Chiesi USA, Inc.11$30,565
Esperion Therapeutics, Inc.61$25,760
Xeris Pharmaceuticals, Inc.128$25,607
Boehringer Ingelheim116$23,579
Recordati_rare_diseases_inc.38$17,719
Amarin Pharma, Inc.65$16,619
Bayer43$11,617
Ascendis Pharma Endocrinology Inc15$9,535
Intuity Medical Inc7$8,660
Mannkind Corporation84$5,221
Johnson & Johnson22$3,626
Madrigal Pharmaceuticals9$3,043
Cequr Corporation5$2,792
Zealand Pharma US, Inc.25$2,370
Insulet Corporation69$1,865
Novartis57$1,071
Radius Health, Inc.56$1,051
Abbott44$850
Dexcom, Inc.31$687
Kyowa Kirin, Inc.16$506
Amneal Pharmaceuticals LLC29$490
Merck27$471
Tandem Diabetes Care, Inc.14$456
Lifescan, Inc.26$424
Antares Pharma, Inc.22$385
Shire North American Group Inc9$347
BD18$337
IBSA Pharma Inc.22$329
Ultragenyx Pharmaceutical Inc.7$271
Valeritas, Inc.6$262
Regeneron Healthcare Solutions, Inc.12$238
Sequel Med Tech, LLC10$222
Pfizer11$209
Merz North America, Inc.1$188
Embecta Corp.11$175
Amphastar Pharmaceuticals, Inc.7$162
BETA Bionics, Inc.9$161
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$117
Halozyme Inc5$101
Nestle Healthcare Nutrition Inc.5$97
Medtronic5$76
Ionis Pharmaceuticals, Inc.3$72
Janssen Scientific Affairs, LLC1$67
Kowa Pharmaceuticals America, Inc.3$58
EUSA Pharma (US) LLC2$45
Neurocrine Biosciences, Inc.2$44
Ascensia Diabetes Care US Inc.2$31
Biogen1$20
Cardinal Health 414 LLC1$18
Roche Diabetes Care, Inc.1$16
Clarus Therapeutics Inc.1$14

How this compares

$2,234,596 in reported general payments places this provider in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida →

Medicare billing

Part B allowed, 2024
$103,856
Medicare patients
268
Services billed
853

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Miami

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →